Tag:

PPD

Latest Headlines

Latest Headlines

PPD beefs up its Irish outpost with a new biologics lab

PPD has amped up the biologics capabilities at its Irish manufacturing operation, opening a new lab devoted to the development of large-molecule treatments.

PPD's in-house biotech pairs up with J&J

X-Chem, a subsidiary of PPD, has signed a deal with Johnson & Johnson to provide its library of molecules to aid in the discovery of new treatments for inflammatory disease.

PPD bets on Japan with new joint venture

PPD has signed a deal with service provider Shin Nippon Biomedical Laboratories to collaborate in Japan, pooling resources in a joint venture designed to tap the growing market for clinical research there.

PPD's X-Chem strikes another deal with Bayer

X-Chem, the biotech that operates from within PPD, signed a second agreement with partner Bayer, outlicensing a second discovery-stage program.

PPD partners up with ERT for data collection

PPD has signed a data-minded deal with the collection experts at ERT, a partnership the companies believe will help their clients conduct more efficient trials.

PPD's X-Chem pairs up with Alexion for drug discovery

X-Chem, PPD's in-house biotech company, has signed a deal with the rare disease specialists at Alexion to lend out its molecular library and help discover new treatments.

PPD teams up with Medidata on risk-based monitoring

PPD has expanded its relationship with eClinical outfit Medidata, combining technologies in risk-based monitoring to help sponsors use real-time safety data to make decisions on clinical trials.

PPD pairs off with Sellas to pick up the pipeline pace

PPD has signed a master service agreement with Swiss biotech Sellas, lending its drug development expertise to the company's efforts to advance a portfolio of treatments.

PPD bets on drug discovery with X-Chem deal

PPD is buying up the entirety of X-Chem, which operates as a biotech within a CRO, marking a vote of confidence in the continued demand for drug discovery services.

PPD looks to tamp down pesky placebos with new trial tech

Countless clinical trials are done in by unexpectedly well-performing placebo arms, a phenomenon particularly common in psychiatric studies. PPD believes a new, proprietary trial design can substantially level the playing field, and the CRO has paid an undisclosed sum to get its hands on the technology.